A school bag on a kitchen table with a folded letter and a small plaster beside it

A letter comes home in the school bag: your 12-year-old is due the HPV vaccine. One dose. If you had the jab yourself, or an older child did, you may remember two — or three. Fewer doses can sound like a cut. The evidence says it's something else: one of the rare cases where medicine learned it had been doing more than it needed to.

What the evidence shows

HPV — human papillomavirus — is a very common virus. A few of its types can, over years, cause cancers of the cervix, mouth, anus, penis, vulva and vagina, as well as genital warts (NHS). Two types, 16 and 18, are the ones the first vaccines were built against, and the ones the big trial tracked.

That trial is called ESCUDDO. In Costa Rica, 20,330 girls aged 12 to 16 were randomised four ways: one or two doses of a vaccine covering two HPV types, or one or two doses of one covering nine (the nine-type vaccine, Gardasil 9, is the one used in the UK). From year one to year five, researchers checked for new infections with HPV 16 or 18 that persisted for at least six months — the step that comes before pre-cancer. The rule was set in advance: one dose would count as "no worse" than two if it allowed no more than 1.25 extra persistent infections per 100 girls (Kreimer et al., New England Journal of Medicine, 2025).

The result: with the two-type vaccine, one dose had 0.13 fewer persistent infections per 100 girls than two doses; with the nine-type vaccine, 0.21 more. Both are far inside the margin. Compared with 3,005 unvaccinated girls and women surveyed alongside the trial, effectiveness was at least 97% in every one of the four groups. No safety concerns emerged. The trial was publicly funded, led by the US National Cancer Institute.

The UK didn't wait for this paper. From 1 September 2023, the programme in England moved from two doses to one for eligible adolescents and for gay, bisexual and other men who have sex with men under 25; Scotland had made the change that January (UKHSA and NHS England). The December 2025 trial is the largest randomised confirmation yet of a decision taken on earlier evidence.

And what does the vaccine do over a lifetime? England is one of the best places on earth to ask, because it has vaccinated girls at 12 to 13 since 2008 and keeps careful cancer records. A 2024 analysis of women aged 20 to 64 found that in the generation offered the vaccine at 12 to 13, cervical cancer rates were 84% lower, and rates of CIN3 — the most serious pre-cancer — 94% lower, than in women never offered it. By mid-2020 the programme had prevented an estimated 687 cancers and about 23,000 pre-cancers. The benefit showed up at every level of deprivation, and the usual gap between richer and poorer areas in cervical cancer had disappeared among those offered the jab (Falcaro et al., BMJ, 2024).

Then, this year, the same group looked at deaths. Among women aged 20 to 24 between 2020 and 2024 — a generation in which about nine in ten had been vaccinated at 12 to 13 — there were no deaths from cervical cancer at all, against 23 expected from historical rates. By the end of 2024 the programme was associated with around 200 cervical cancer deaths averted (Sasieni and Falcaro, The Lancet, 2026). Those were the two- and three-dose generations; the one-dose generation is only just setting out.

What's still uncertain

Five years, not fifty. The trial measured persistent infection, not cancer, because cancer takes decades to appear. That is the accepted way to test these vaccines quickly — but whether one dose holds up as long as two over a lifetime is a question only time can answer. England's records will be watched closely.

Girls aged 12 to 16. The trial says nothing directly about adults vaccinated later, about people with weakened immune systems, or about boys — which is one reason most, but not all, people under 25 in the UK get a single dose, while some groups are still offered more. The NHS page has the details for each.

Age matters. In the English data, the generations offered catch-up vaccination at 14 to 18 saw smaller reductions in pre-cancer than those vaccinated at 12 to 13. The vaccine works best before any exposure to the virus — which is why the school letter arrives when it does.

What you'll hear online

"One dose is a cost-cutting exercise." The trial that settled this was paid for by a public cancer institute and was designed to detect whether one dose was worse — it wasn't. Fewer doses means fewer missed second appointments, fewer needles and more children fully protected. That is not a cut; it's a correction.

What you can do

Check. If you, or your child, are under 25 and missed the vaccine, it is still free until your 25th birthday (for boys, if born after 1 September 2006). Men who have sex with men can have it up to their 46th birthday through a sexual health clinic. Ask your doctor's surgery or the school immunisation team whether you're up to date — and, if your health history puts you in a group that needs more than one dose, how many.

Sometimes the good news arrives folded in a school bag. This is one of those times.

— Dr. Brugal

More from our NHS Today series and on sexual health:

References

All studies retrieved via PubMed.

  1. Kreimer AR, Porras C, Liu D, et al. Noninferiority of One HPV Vaccine Dose to Two Doses. New England Journal of Medicine. 2025;393(24):2421-2433. Randomised non-inferiority trial (ESCUDDO), 20,330 girls aged 12 to 16, infections tracked from month 12 to month 60. doi:10.1056/NEJMoa2506765 (PMID 41337735)
  2. Falcaro M, Soldan K, Ndlela B, et al. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study. BMJ. 2024;385:e077341. Population-based observational study in England, women aged 20 to 64, 2006 to 2020. doi:10.1136/bmj-2023-077341 (PMID 38749552)
  3. Sasieni P, Falcaro M. Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data. The Lancet. 2026;408(10550):162-168. Population-based observational analysis of mortality data in England, women aged 20 to 34, 2001 to 2024. doi:10.1016/S0140-6736(26)00918-9 (PMID 42309117)

Awareness content — not medical advice. Always talk to your doctor or pharmacist before making changes.